ESG Data

アンカーリンク用

Sustainability data is presented on this page. Please refer to our annually published Sustainability Reports for historical data.
To ensure the reliability of the reported figures, we have received third-party assurance for some of the environmental and social data in the “SUSTAINABILITY DATA 2026 (PDF version)”. In the “SUSTAINABILITY DATA 2026 (PDF version),” data for FY2025 that has received assurance is marked with ★.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

[Data Coverage]
Non-Consolidated ONO PHARMACEUTICAL CO., LTD.: Fujiyama Plant/Yamaguchi Plant /Joto Pharmaceutical Product Development Center/ Minase Research Institute/Tsukuba Research Institute/Former Fukui Research Institute/Offices including the Head Office
Consolidated All companies included in the consolidated financial statements.
  • If the data coverage is different from the above, it is specified in each table.

Due to rounding of the figures in the table, the breakdown totals may not always equal the overall totals (Same as environmental data below).

Scope 1+2 GHG Emissions (Unit: t-CO2)
Item Data Coverage FY2024
(Base year)		 FY2025
Scope 1 (Breakdown by GHG type) Energy-derived Non-consolidated 8,769.7 8,486.1
Consolidated 9,517.1 9,134.3
Non-energy-derived (HFCs, HCFCs, CH4, N2O） Non-consolidated 617.9 862.7
Consolidated 617.9 862.8
Total Non-consolidated 9,387.6 9,348.8★
Consolidated 10,135.0 9,997.1★
Scope 2 (Market-based)*1 Non-consolidated 1,143.2 329.6★
Consolidated 3,687.7 2,749.6★
Scope 2 (Location-based)*2 Non-consolidated 18,293.7 17,896.1★
Consolidated 21,057.7 20,542.4★
Scope 1+2 (Market-based）(a) Non-consolidated 10,530.9 9,678.4
Consolidated 13,822.7 12,746.7
Scope 1+2 (Location-based) Non-consolidated 27,681.3 27,244.9
Consolidated 31,192.7 30,539.5
Amount of CO2 offset due to voluntary credit (Carbon-neutral city gas purchased) (b) Non-consolidated 6,899.4 9,678.4
Consolidated 6,899.4 9,678.4
GHG emissions after offset (a-b) Non-consolidated 3,631.5 0.0
Consolidated 6,923.3 3,068.3
  • Starting from Fiscal Year 2024 (“FY2024“), our calculation method for greenhouse gas emissions has been revised based on the principles of the GHG Protocol.
    The calculation methods for data from previous years are described in the sustainability data for those respective years.
  • The following emission factors for electricity are used.
    〈For non-consolidated and Japanese group companies〉: The emission factor for each electric utility for the relevant fiscal year, minus the transmission and distribution loss factor（IEA*3 Emission Factors – 2025: T&D losses adjustment [(gCO2/kWh)]）is used.
    〈For Overseas group companies〉: The country-specific emission factor from IEA*3 Emission Factors 2025: CO2 emissions per kwh of electricity only [gCO2/kWh] is used.
  • The following emission factors for electricity are used.
    〈For non-consolidated and Japanese group companies〉: The country-specific emission factor from IEA*3 Emission Factors 2025: CO2 emissions per kwh of electricity only [gCO2/kWh] is used.
    〈For Overseas group companies〉: The country-specific emission factor from IEA*3 Emission Factors 2025: CO2 emissions per kwh of electricity only [gCO2/kWh] is used.
  • IEA: International Energy Agency
Scope 3 GHG Emissions (Unit: t-CO2)
Category Calculation method / notes Data Coverage FY2024
(Base year)		 FY2025
01 Purchased goods and services Calculated by multiplying the purchase amount of raw materials, purchased goods, and indirect procurement (such as software, equipment, and materials) by the emission factor. Consolidated 331,661.1 267,681.4★
02 Capital goods Calculated by multiplying the amount of purchased or acquired tangible fixed assets and intangible assets (such as software) by the emission factor. Consolidated 28,728.5 26,637.7★
03 Fuel- and energy related activities not included in Scope 1 or Scope 2 Calculated by multiplying the amount of purchased electricity (excluding renewable energy*1), city gas, gaseous fossil fuels, liquid fossil fuels, and gasoline used by each emission factor. Non-consolidated 1,961.2 2,140.1
Consolidated 2,782.4 2,875.4
04 Upstream transportation and distribution
  1. If emission data from joint transportation partners is available, it is used.
  2. If not, emissions are calculated by multiplying transportation data from our factories and logistics centers to pharmaceutical wholesalers by the emission factor*2.
 Non-consolidated 241.0 583.3
Consolidated*3 457.1 690.1
05 Waste generated in operations Calculated by multiplying the amount of waste by type and treatment method by the emission factor (including waste transportation). Non-consolidated 246.1 233.2
Consolidated 281.0 266.6
06 Business travel Calculated by multiplying the amount of transportation expenses paid for business trip by the emission factor. Non-consolidated 4,038.0 3,690.6
Consolidated*4 7,825.0 9,353.5
07 Employee commuting Calculated by multiplying the amount paid for commuting transportation by the emission factor. Non-consolidated 718.0 838.6
Consolidated*5 836.3 918.8
08 Upstream leased assets Not relevant - - -
09 Downstream transportation and distribution
  1. Calculated by multiplying the Scope 1+2 greenhouse gas emissions of major pharmaceutical wholesalers by the ratio of our transaction value to their total sales.
  2. Calculated by multiplying transportation and delivery costs by the emission factor.
 Non-consolidated 7,734.0 4,514.7
Consolidated*6 8,498.9 5,023.6
10 Processing of sold products Not relevant - - -
11 Use of sold products Not relevant - - -
12 End-of-life treatment of sold products Calculated by multiplying the amount of containers and packaging used (as surveyed) by the emission factor for each type of waste. Non-consolidated 616.3 612.0
Consolidated*7 696.0 723.5
13 Downstream leased assets Not relevant - - -
14 Franchises Not relevant - - -
15 Investments Calculated by multiplying the Scope 1+2 GHG emissions of investee companies by our equity ownership ratio Non-consolidated 15,497.0 14,669.1
Total Consolidated 397,263.3 328,839.8
  • Starting from Fiscal Year 2024 (“FY2024“), our calculation method for greenhouse gas emissions has been revised based on the principles of the GHG Protocol.
    The calculation methods for data from previous years are described in the sustainability data for those respective years.
    The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (Ver.3.5)," published by the Ministry of the Environment, Government of Japan.
  • For renewable energy, it is limited to sources such as solar and wind power that are provided under the power supply plans contracted with the energy company.
  • For category 4, GHG emissions for group companies other than the non-consolidated are calculated by multiplying the transportation costs (upstream) paid by each group company by the emission factor. Based on the contractual arrangements between ONO PHARMACEUTICAL CO., LTD. and its group companies, when ONO PHARMACEUTICAL CO., LTD. pays the transportation costs, the GHG emissions are calculated by multiplying those costs by the emission factor and are counted as ONO PHARMACEUTICAL's category 4 emissions.
  • Non-consolidated, Ono Pharma Healthcare Co., Ltd., ONO PHARMA KOREA CO. LTD., ONO PHARMA TAIWAN CO. LTD., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO. LTD., michiteku Co., Ltd., Deciphera Pharmaceuticals Inc.
  • Non-consolidated, Ono Pharma Healthcare Co., Ltd., Ono Digital Health Investment, GK., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO. LTD., ONO PHARMA TAIWAN CO. LTD., Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO. LTD., michiteku Co., Ltd., OPhrs Co., Ltd., Ono Venture Investment, Inc., Deciphera Pharmaceuticals Inc.
  • Non-consolidated, Ono Pharma Healthcare Co., Ltd., Ono Digital Health Investment, GK., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO. LTD., ONO PHARMA TAIWAN CO. LTD., Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO. LTD., michiteku Co., Ltd., OPhrs Co., Ltd., Ono Venture Investment, Inc., Deciphera Pharmaceuticals Inc.
  • Non-consolidated, Ono Pharma Healthcare Co., Ltd., ONO PHARMA KOREA CO. LTD., ONO PHARMA TAIWAN CO. LTD., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO. LTD., Deciphera Pharmaceuticals Inc.
  • Non-consolidated, Ono Pharma Healthcare Co., Ltd., ONO PHARMA KOREA CO. LTD., ONO PHARMA TAIWAN CO. LTD., Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO. LTD., Deciphera Pharmaceuticals Inc.
Please see here for the GHG emissions data for FY2024 calculated using the conventional method.
[Data Coverage]
Consolidated All companies included in the consolidated financial statements.
Non-consolidated ONO PHARMACEUTICAL CO.,LTD.: Fujiyama Plant/Yamaguchi Plant (since FY2018 - )/Joto Pharmaceutical Product Development Center/ Minase Research Institute/Tsukuba Research Institute/Former Fukui Research Institute/Offices including the Head Office
ONO Group FY2024 ONO PHARMACEUTICAL CO.,LTD., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd., michiteku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
FY2022 and FY2023 ONO PHARMACEUTICAL CO.,LTD., ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd.
  • If the data coverage is different from the above, it is specified in each table.
  • For FY2024 data coverage , michiteku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., and BEE BRAND MEDICO DENTAL. CO., LTD. are added to those of FY2023.

Due to rounding of the figures in the table, the breakdown totals may not always equal the overall totals (Same as environmental data below)

Scope 1+2 GHG Emissions (Unit: kt-CO2)
Item Data Coverage FY2017
(Base year)		 FY2021 FY2022 FY2023 FY2024★
Scope 1 (Breakdown by GHG type) Energy-derived Non-consolidated 8.5 9.8 8.0 6.6 7.0
ONO Group - - 8.0 6.6 7.4
Non-energy-derived (HFCs, HCFCs) Non-consolidated 0.2 0.0 0.2 0.1 0.6
ONO Group - - 0.2 0.1 0.6
Total Non-consolidated 8.7 9.8 8.2 6.7 7.7
ONO Group - - 8.2 6.7 8.1
Scope 2 Non-consolidated 21.1 13.7 10.2 9.4 1.2
ONO Group - - 10.4 9.5 3.1
Scope 1+2 (Total) (a) Non-consolidated 29.8 23.6 18.4 16.0 8.9
ONO Group - - 18.6 16.2 11.2
Amount of CO2 offset due to voluntary credit (Carbon-neutral city gas purchased) (b) Non-consolidated 0.0 0.6 0.7 1.7 6.9
ONO Group - - 0.7 1.7 6.9
GHG emissions after offset (a-b) Non-consolidated 29.8 23.0 17.7 14.4 2.0
ONO Group - - 17.9 14.5 4.3
  • GHG emissions are calculated using the following formula. These are market-based data.
    [Japanese bases] Calculated in accordance with the Act on Promotion of Global Warming Countermeasures.
    [Overseas bases] Calculated by multiplying the amount of electricity purchased by overseas based by the country-specific emission factor published in the UNFCCC The IFI Dataset of Default Grid Factors (v3.1).
Scope 3 GHG Emissions (Unit: kt-CO2)
Category Calculation method / notes Data Coverage FY2017
(Base year)		 FY2021 FY2022 FY2023 FY2024★
01 Purchased goods and services Calculated by multiplying the Scope 1+2 and Scope 3 Upstream (category 1 to 8) GHG emissions of our major suppliers of raw materials (covering more than 80% of the purchase price of raw materials) by our transaction volume as a percentage of the sales volume of the suppliers. For suppliers of raw materials other than those mentioned above, the calculation is based on the ratio of GHG emissions to the transaction value of major suppliers *3 Non-consolidated 56.5*1 89.1*1 54.4*1 59.6*1 - *2
ONO Group*8 - - - 64.0 - *2
02 Capital goods Calculated by multiplying the price of capital goods treated as fixed assets (investment in the expansion and maintenance of facilities), excluding land, by the emission factor. Consolidated 52.6 26.4 21.3 18.4 22.8
03 Fuel- and energy related activities not included in Scope 1 or Scope 2 Calculated by multiplying the amount of purchased electricity (excluding renewable energy*4) by the emission factor. Non-consolidated 1.5 3.0 2.8 2.9 2.7
ONO Group*9 - - - 3.1 3.0
04 Upstream transportation and distribution Calculated by multiplying the emission factor by the transportation data from our own production sites and distribution centers to the delivery destination *5 Non-consolidated 0.1 0.1 0.1 0.4*1 0.3
ONO Group*10 - - - 0.5 0.4
05 Waste generated in operations Calculated by multiplying the weight value of waste by an emission factor for each type of waste. Non-consolidated 0.3 0.3 0.3 0.3 0.2
ONO Group*11 - - - 0.3 0.3
06 Business travel Calculated by multiplying the amount of transportation expenses paid by airplanes and Shinkansen by the emission factor. Non-consolidated 2.5 0.5 1.3 3.1 4.0
ONO Group*12 - - - 4.4 4.8
07 Employee commuting ・Calculated by multiplying the amount paid for commuting transportation by the emission coefficient.
・Including commuting by car from FY2021		 Non-consolidated 0.4 0.7 0.7 0.7 0.7
ONO Group*13 - - - 0.7 0.8
08 Upstream leased assets Calculated by multiplying the fuel consumption of leased cars by the emission factor*6 Non-consolidated 3.5 2.1 1.9 1.9 1.7
ONO Group*14 - - - 2.1 1.8
09 Downstream transportation and distribution Calculated by multiplying the Scope 1+2 GHG emissions of our major pharmaceutical wholesalers by the value of our transactions as a percentage of the sales volume of our major pharmaceutical wholesalers*7 Non-consolidated 5.3 5.5 7.5 7.6 -*2
10 Processing of sold products Not relevant - - - - - -
11 Use of sold products Not relevant - - - - - -
12 End-of-life treatment of sold products Calculated by multiplying the weight of sold product containers and packaging by the emission factor. Non-consolidated 0.1 0.2 0.2 0.2 0.2
ONO Group*15 - - - 0.2 0.2
13 Downstream leased assets Calculated by multiplying the floor area of the building in question by the emission factor for each use*7 Non-consolidated 0.3 0.3 0.3 0.3 0.0
14 Franchises Not relevant - - - - - -
15 Investments Calculated by multiplying the Scope 1+2 GHG emissions of investee companies by our equity ownership ratio*16. Non-consolidated - - - 0.4 -*2
Total Non-consolidated 123.1 128.1 90.8 95.7 - *2
ONO Group - - - 101.9 - *2
  • The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2017, Ver. 2.4;, FY2021, Ver. 3.2; FY2022, Ver. 3.3, FY2023, Ver. 3.4, FY2024, Ver.3.5)," published by the Ministry of the Environment, Government of Japan.
    Since only non-consolidated data is available for FY 2017, FY2021, and FY2022, the ONO Group data is indicated as “–”.
  • Due to revision of the calculation methods, non-consolidated data for category 1(FY2017, FY2021, and FY2022), and for category 4 (FY2023) have been revised. Based on the previous calculation method, GHG emissions for Category 1 in FY2017, FY2021, FY2022, and FY2023 were 8.5 kt-Co2, 13.8 kt-CO2, 4.8 kt-CO2, and 4.3 kt-CO2, respectively.
    [Previous calculation method: Calculated by multiplying the Scope 1+2 GHG emissions of our major suppliers of raw materials (covering more than 80% of the purchase price of raw materials) by our transaction volume as a percentage of the sales volume of the suppliers.  For suppliers of raw materials other than those mentioned above, the calculation is based on the ratio of GHG emissions to the transaction value of major suppliers.] 
  • Categories 1, 9, 15, and the total for FY2024 (non-consolidated and ONO group) are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.
  • For category 1, GHG emissions for group companies other than non-consolidated are calculated by multiplying the purchase amount of the main products for their business by the emission factor.
  • For renewable energy, it is limited to sources such as solar and wind power that are provided under the power supply plans contracted with the energy company.
  • For category 4, GHG emissions for group companies other than the non-consolidated are calculated by multiplying the transportation costs (upstream) paid by each group company by the emission factor. Based on the contractual arrangements between ONO PHARMACEUTICAL CO., LTD. and its group companies, when ONO PHARMACEUTICAL CO., LTD. pays the transportation costs, the GHG emissions are calculated by multiplying those costs by the emission factor, and are counted as ONO PHARMACEUTICAL's category 4 emissions.
  • For category 8, GHG emissions for group companies other than the non-consolidated are calculated by multiplying either the amount of fuel consumed or the fuel costs for leased company cars by the emission factor.
  • For categories 9 and 13, group companies other than the non-consolidated are not included.
  • Non-consolidated, Ono Pharma UD Co., Ltd., michiteku Co.,Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
  • Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA UK LTD., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
  • Non-consolidated, ONO PHARMA TAIWAN CO., LTD., michiteku Co.,Ltd.(data for FY2023 is not included in the calculation), TOYO Pharmaceutical Co., Ltd.
  • Non-consolidated, Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation), TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD. (data for FY2023 is not included in the calculation).
  • Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., michiteku Co.,Ltd. (data for FY2023 is not included in the calculation), TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
  • Non-consolidated, ONO PHARMA USA, INC., ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation), michiteku Co.,Ltd. (data for FY2023 is not included in the calculation), TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
  • Non-consolidated, ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD., Ono Pharma UD Co., Ltd. (data for FY2023 is not included in the calculation), BEE BRAND MEDICO DENTAL. CO., LTD.
  • Non-consolidated, TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD.
  • For Category 15, GHG emissions are calculated based only on the investee companies that disclose their Scope1+2 GHG emissions. 
✖ Close
Energy Consumption (Unit: MWh)
Item Data Coverage FY2022 FY2023 FY2024 FY2025★
Energy consumption Non-consolidated 86,067.6 82,285.0 83,748.9 83,804.1
Consolidated 86,411.7 82,666.1 90,726.7 93,666.7
Total Electricity Consumption and Renewable Energy Usage rate
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Electricity consumption Private power generation
(renewable energy: solar power generation)		 Non-consolidated MWh 64.4 64.0 63.6 69.9
Consolidated 64.4 64.0 63.6 69.9
Purchased electricity
(renewable energy: physical PPA)		 Non-consolidated 0.0 0.0 533.0 2,647.6
Consolidated 0.0 0.0 533.0 2,647.6
Purchased electricity
(renewable energy)		 Non-consolidated 3,480.0 20,281.2 37,336.4 36,505.9
Consolidated 3,480.0 20,281.2 37,336.4 36,505.9
Private power generation
(non-renewable energy)		 Non-consolidated 7,285.0 5,596.7 6,634.1 6,731.0
Consolidated 7,285.0 5,596.7 6,634.1 6,731.0
Purchased electricity
(non-renewable)		 Non-consolidated 37,821.6 21,543.7 2,756.2 771.7
Consolidated 38,165.3 21,924.4 7,249.2 7,271.5
Total
(total electricity consumption)		 Non-consolidated 48,651.0 47,485.5 47,323.4 46,726.2
Consolidated 48,994.7 47,866.3 51,816.4 53,226.0
Renewable energy certificate usage Solar power generation Non-consolidated MWh 0.0 0.0 0.0 771.7
Consolidated 6,907.0 0.0 0.0 771.7
Renewable energy usage* Non-consolidated MWh 10,451.4 20,345.2 37,933.1 39,995.1★
Consolidated 10,451.4 20,345.2 37,933.1 39,995.1★
Renewable energy usage rate
(renewable energy usage / total electricity consumption)		 Non-consolidated % 21.5 42.8 80.2 85.6
Consolidated 21.3 42.5 73.2 75.1
  • Renewable energy usage = Private power generation (renewable energy = solar power generation) + Purchased electricity (physical PPA) + Purchased electricity (renewable energy) + Renewable energy certificate usage (Solar power generation).
Water Intake and Discharged Water Volume by Site (Unit: 1,000 m3)
Data Coverage Site Name Water stress*1 FY2022 FY2023 FY2024 FY2025★
Water intake volume Discharged water volume Water intake volume Discharged water volume Water intake volume Discharged water volume Water intake volume Discharged water volume
Non-consolidated Fujiyama Plant Low - Medium risk 122.9 100.1 115.8 94.6 127.3 98.2 117.5 85.5
Yamaguchi Plant Medium - High risk 22.8 20.9 24.4 22.9 23.8 23.6 21.5 20.6
Joto Pharmaceutical Product Development Center Low - Medium risk 3.4 3.4
 3.7 3.7 3.5 3.5 2.9 3.2
Minase Research Institute Low - Medium risk 32.2 32.2 30.1 30.0 34.0 32.9 30.1 30.0
Tsukuba Research Institute Medium - High risk 0.8 0.2 5.0 5.0 3.6 3.2 3.5 3.5
Former Fukui Research Institute*2 Low - Medium risk 4.7 4.7 - - - - - -
Offices including the Head Office Low - Medium risk or Medium - High risk 9.5 9.5 10.6 10.6 10.4 10.4 10.5 10.5
Total 196.4 171.2 189.6 166.7 202.8 171.9 186.0 153.4
Group companies*3 Low - Medium risk - - 23.5 18.6 23.1 17.1 24.1 16.6
Non-consolidated and Group companies*3 196.4 171.2 213.0 185.3 225.9 189.0 210.1 170.0
  • Evaluation results based on WRI Aqueduct (baseline, confirmed as of March 2026)
  • For Former Fukui Research Institute, there has been no water usage since FY2023.
  • The data includes Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., and BEE BRAND MEDICO DENTAL. CO., LTD. in FY2023, and Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD, and Deciphera Pharmaceuticals Inc. in FY2024 onwards.
Water Intake Volume by Source and Discharged Water Volume by Destination (Unit: 1,000 m3)
Item Data Coverage FY2022 FY2023 FY2024 FY2025★
Water intake volume City water FY2022: Non-consolidated
FY2023: Non-consolidated and Group companies*		 180.6 198.8 212.2 198.8
Groundwater 15.3 13.4 13.0 10.7
Industrial water 0.5 0.8 0.7 0.6
Total of water intake volume 196.4 213.0 225.9 210.1
Discharged water volume Fresh surface water FY2022: Non-consolidated
FY2023: Non-consolidated and Group companies*		 121.1 117.4 121.8 106.2
Third party destinations 50.1 67.9 67.2 63.8
Sea 0.0 0.0 0.0 0.0
Groundwater 0.0 0.0 0.0 0.0
Total of discharged water volume 171.2 185.3 189.0 170.0
Total of water consumption FY2022: Non-consolidated
FY2023: Non-consolidated and Group companies*		 25.2 27.7 36.9 40.1
  • The data includes Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., and BEE BRAND MEDICO DENTAL. CO., LTD. in FY2023, and Ono Pharma UD Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL. CO., LTD, and Deciphera Pharmaceuticals Inc. in FY2024 onwards.
Waste Management, Recycling Containers and Product Packaging
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Industrial waste Waste generated Non-consolidated t 492.8 569.7 818.6 479.8★
Non-consolidated and Group companies *1 - 620.6 869.7 528.9★
[Waste breakdown]
Special management industrial waste (hazardous waste)*2		 Non-consolidated t 142.5 145.5 128.4 144.2★
Non-consolidated and Group companies *1 - 149.7 133.4 148.1★
final landfill disposal Non-consolidated t 0.1 0.1 0.0 0.3★
Non-consolidated and Group companies *1 - 6.7 7.9 6.6★
final landfill disposal rate Non-consolidated % 0.02 0.02 0.00 0.05★
Non-consolidated and Group companies *1 - 1.09 0.91 1.25★
Final landfill disposal (Non-industrial waste is included) Non-consolidated t 4.4 3.5 3.2
Container and packaging usage Plastic Non-consolidated t 173.4 193.5 207.6 206.8
Paper t 163.4 163.8 163.3 151.7
Glass (colorless) t 0.0 0.0 0.0 0.0
Glass (brown) t 0.2 0.2 0.1 0.1
Obligatory recycling amount Plastic Non-consolidated t 52.2 56.2 60.0 67.1
Paper t 0.8 0.8 0.8 1.2
Glass (colorless) t 0.0 0.0 0.0 0.0
Glass (brown) t 0.0 0.0 0.0 0.0
Commissioning fee paid for recycling Non-consolidated 1,000 yen 3,049 3,506 3,879 4,787
  • Data includes TOYO Pharmaceutical Co., Ltd. from FY2023 onwards.
  • Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or the potential to cause damage to human health or the living environment.
  • Waste data includes logistics centers from FY2021. The former Fukui Research Institute is included up to FY2023.
Prevention of Air Pollution and Water Pollution
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Emissions into the air SOx Non-consolidated t 0.0 0.0 0.0 0.0
NOx t 4.9 5.0 6.0 5.7
Particulate matter t 0.3 0.3 0.3 0.3
PRTR substance t 0.3 0.0* 0.0* 0.0*
Emissions into water Wastewater 1,000 m3 171.2 166.7 171.9 153.4
BOD t 1.2 0.8 0.8 0.8
PRTR substance t 0.0 0.0* 0.0* 0.0*
  • Acetonitrile has been excluded from the PRTR substances since FY2023.
Management of Chemicals (PRTR substances)
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Amount handled by the notified facilities Acetonitrile Non-consolidated t 6.9 -* -* -*
Normal-hexane t 1.8 1.7 1.7 1.8
Total t 8.7 1.7 1.7 1.8
Dioxins mg-TEQ - - - -
Notified release (into the air) Acetonitrile t 0.3 -* -* -*
Normal-hexane t 0.0 0.0 0.0 0.0
Total t 0.3 0.0 0.0 0.0
Dioxins mg-TEQ - - - -
Notified release (into public waters) Acetonitrile t 0.0 -* -* -*
Normal-hexane t 0.0 0.0 0.0 0.0
Total t 0.0 0.0 0.0 0.0
Dioxins mg-TEQ - - 　 -
Notified transfer (contained in waste) Acetonitrile t 6.6 -* -* -*
Normal-hexane t 1.8 1.7 1.7 1.8
Total t 8.4 1.7 1.7 1.8
Dioxins mg-TEQ - - - -
Notified transfer (Into public sewage) Acetonitrile t 0.0 -* -* -*
Normal-hexane t 0.0 0.0 0.0 0.0
Total t 0.0 0.0 0.0 0.0
Dioxins mg-TEQ - - - -
  • Acetonitrile has been excluded from the PRTR substances since FY2023.
Environmental Management
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Acquisition rate of ISO 14001 certification for production sites Non-consolidated % 100 100 100 100
Environmental Violation
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Number of breaches of legal obligation/regulatory violations Non-consolidated Cases 0 0 0 0
Amount of breach-/violation-related fines Million Yen 0 0 0 0
Environmental liabilities as of fiscal year-end Million Yen 0 0 0 0
  • Breach/violation with a fine of US$10,000 or more are covered. The above includes violations related to air and soil pollution, noise, vibration, and water quality.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

[Data Coverage]
Consolidated All companies included in the consolidated financial statements.
Non-consolidated ONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Composition of Board of Directors Directors (Total) Non-consolidated Persons 8 7 6 6
Outside Directors Non-consolidated Persons 3 3 3 3
Female Directors Non-consolidated Persons 1 1 1 1
Composition of Audit & Supervisory Board Audit & Supervisory Board Members (Total) Non-consolidated Persons 4 4 4 4
Outside Audit ＆ Supervisory Board Members Non-consolidated Persons 2 2 2 2
Female Outside Audit ＆ Supervisory Board Members Non-consolidated Persons 1 1 1 1
Number of the Meeting of the Board of Directors Non-consolidated Times 12 12 12 12
Number of the Meeting of the Audit & Supervisory Board Non-consolidated Times 15 15 15 15
Attendance rate at the Meeting of the Board of Directors Directors Non-consolidated % 100 94.0 100 100
Audit ＆ Supervisory Board Members Non-consolidated % 97.9 100 100 100
Compliance
Item Data Coverage Unit FY2022 FY2023 FY2024 FY2025
Compliance training attendance rate Non-consolidated % 100 100 100 100
Number of reports Bribery cases Non-consolidated Incidents 0 0 0 0
Discrimination and harassment related Non-consolidated Incidents 22 25 20 24
Personnel and labor management related Non-consolidated Incidents 6 8 5 2
Customer privacy data related Non-consolidated Incidents 0 0 0 0
Conflicts of interest related Non-consolidated Incidents 0 0 0 0
Money laundering or Insider trading related Non-consolidated Incidents 0 0 0 0
Others Non-consolidated Incidents 22 16 18 18
Total Non-consolidated Incidents 50 49 43 44
Number of compliance violations（Disciplinary action cases） Bribery cases Non-consolidated Incidents 0 0 0 0
Discrimination and harassment related Non-consolidated Incidents 4 5 2 2
Personnel and labor management related Non-consolidated Incidents 0 0 0 0
Customer privacy data related Non-consolidated Incidents 0 0 0 0
Conflicts of interest related Non-consolidated Incidents 0 0 0 0
Money laundering or Insider trading related Non-consolidated Incidents 0 0 0 0
Others Non-consolidated Incidents 9 1 2 3
Total Non-consolidated Incidents 13 6 4 5
Costs for legal violations Non-consolidated Million yen 0 0 0 0
Number of facilitation payments Non-consolidated Incidents 0 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system